Nordic Cryobank Group ApS - NCB - (European Sperm Bank) - 5971

Safety warnings | Blood & Tissue | 19/12/2017

The Federal Office for Safety in Health Care has been informed by the Danish authority that the Danish tissue bank Cryos International ApS (DK257551) of the disease of a child conceived with the child conceived with semen from sperm donor 5971.

The report of the disease described a child with a delay in both motor and general development. general development.

The child exhibited brachycephaly and plagiocephaly, and MRI of the Cerebrum was unremarkable.

Autism spectrum disorders show a complex inheritance pattern, and it has been calculated based on risk assessment that the risk of a child from this donor developing autism is 5-7 is 5-7%.

Genetic studies have revealed a 178 kb duplication on chromosome 14q32.11, which covers part of the TTC7B gene.

The clinical significance of the duplication is not known.The result of genetic testing showed that the donor is also a carrier of the same duplication that is also present in the child.

Since the donor does not show any abnormalities and no phenotype is present in the donor or in the donor's family, a connection between the duplication and the relationship between the duplication and the phenotype of the child is not likely.

However, it cannot be excluded that the child's disease is caused by a genetic disease with a recessive pattern of inheritance.

If this is the case, the risk is of having a child with a recessive disease, provided that the recipient also has a mutation of the same gene. also has a mutation of the same gene as the donor, is 25%.

All clinical and private users who have received the sperm donation from this donor have been informed according to the Danish Tissue Bank.

Sperm donations from this donor (including embryos) may continue to be used for parents who already have a parents who already have a child from this donor - but only on the condition that the parents have been However, this is only possible if the parents have been informed in writing and accept the risk.

Email

Further inquiry note